Privately-held NovImmune SA of Geneva, Switzerland has announced the start of a proof-of-concept study of a monoclonal antibody intended to neutralise the activity of the chemokine, IP-10, in order to treat patients with primary biliary cirrhosis. ---Subscribe to MedNous to access this article--- Company News Research & University News